Infective Endocarditis

Endocarditis – High‑Yield Study Guide for Medical Students

Definition

Infective endocarditis (IE) is an infection of the endocardial surface of the heart, most commonly involving the cardiac valves, characterized by bacterial or, less commonly, fungal colonization of damaged endocardium with formation of vegetations composed of platelets, fibrin, microorganisms, and inflammatory cells.^[3]

IE is classically categorized as:

• Native valve endocarditis (NVE) – infection of structurally normal or abnormal native valves.
• Prosthetic valve endocarditis (PVE) – early (<12 months) or late (>12 months) after valve implantation.
• Device-related endocarditis – infection involving pacemaker/ICD leads, intracardiac devices, or long-term catheters (e.g., Permcath).^[1]

Epidemiology

IE is relatively uncommon but associated with high morbidity and mortality. Incidence in high-income countries is approximately 3–10 cases per 100,000 person‑years, with an increasing proportion of cases related to health‑care exposure, prosthetic valves, intracardiac devices, and chronic hemodialysis catheters.^[1]

Major epidemiologic trends include:

• Age shift – more cases in older adults with degenerative valve disease and multiple comorbidities.
• Health‑care associated IE – related to intravascular catheters, prosthetic material, and invasive procedures.^[1]
• Prosthetic valves and paravalvular leaks – PVE and paravalvular leak devices are important substrates for IE and its complications.^[5]
• Oral health – poor dental hygiene and untreated dental disease remain key reservoirs for bacteremia with viridans streptococci and other oral flora.^[4]

Pathophysiology

The pathogenesis of IE requires two key steps:

• Endothelial injury – turbulent flow across abnormal valves (rheumatic, degenerative, congenital lesions), prosthetic material, or high-velocity jets (e.g., paravalvular leak) causes endothelial disruption. This promotes deposition of platelets and fibrin, forming sterile nonbacterial thrombotic endocardial lesions.
• Transient bacteremia or fungemia – procedures involving mucosal surfaces (dental, respiratory, GI/GU), IV drug use, or intravascular devices introduce microorganisms that adhere to the damaged endocardium, colonize, and proliferate within vegetations.^[4]

Once established, vegetations:

• Protect organisms from host defenses and antibiotics due to high bacterial burden and limited penetration.
• Can embolize, causing infarction or metastatic infection (e.g., brain, spleen, kidneys).
• Lead to valvular destruction, regurgitation, abscess formation, conduction abnormalities, and heart failure.^[8]

Etiology and Microbiology (High‑Yield)

Common causative organisms depend on host factors and exposure:

• Native valve (community-acquired)
  • Viridans group streptococci – associated with poor dentition and dental procedures.
  • Staphylococcus aureus – including MRSA; increasingly common, often aggressive with rapid valve destruction.
  • Enterococci – often from GI or GU sources.
• Healthcare-associated / prosthetic valve / device-related
  • Staphylococcus aureus – frequent cause, especially in catheter-related infections and hemodialysis patients.^[1]
  • Coagulase-negative staphylococci – common in early prosthetic valve endocarditis.
  • Gram-negative bacilli and fungi – less common but serious.
• Special groups
  • HACEK organisms (Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella) – fastidious gram-negative bacilli causing subacute IE; rare but classically exam-relevant.^[8]
  • Non-tuberculous mycobacteria (NTM) – rare, opportunistic cardiac infections including pericardial and endocardial involvement.^[9]

Risk Factors

High‑yield risk factors for endocarditis include:

• Pre‑existing valvular heart disease (rheumatic, bicuspid aortic valve, mitral valve prolapse with regurgitation).
• Prosthetic heart valves and paravalvular leak devices.^[5]
• Intracardiac devices – pacemaker/ICD leads, left ventricular assist devices.
• Chronic hemodialysis and long-term central venous catheters (Permcath, tunneled lines).^[1]
• Intravenous drug use (IVDU) – commonly involves the tricuspid valve with S. aureus.
• Congenital heart disease – especially cyanotic lesions or residual defects after repair.
• Immunosuppression – including HIV, chemotherapy, prolonged steroids.
• Poor oral hygiene, extensive dental disease, or invasive dental procedures without adequate prophylaxis in high‑risk patients.^[4]

Clinical Presentation

Presentation ranges from indolent subacute disease to fulminant sepsis. Always think about IE in patients with unexplained fever plus a predisposing cardiac lesion or intravascular device.

Constitutional and Cardiac Symptoms

• Fever – most common symptom; may be low‑grade in subacute IE.
• Chills, night sweats, malaise, anorexia, weight loss.
• New or changing heart murmur – due to evolving valvular regurgitation.
• Dyspnea, orthopnea, edema – suggestive of heart failure from acute valvular insufficiency.
• Pleuritic chest pain – can indicate pulmonary emboli in right‑sided IE.

Peripheral Manifestations and Embolic Phenomena

Classic peripheral signs are less common today but remain high‑yield for exams:

• Splinter hemorrhages – linear reddish‑brown streaks under the nails.
• Janeway lesions – painless, erythematous macules on palms and soles (septic microemboli).
• Osler nodes – painful, tender nodules on finger and toe pads (immune complex mediated).
• Roth spots – retinal hemorrhages with pale centers.
• Splenomegaly – more frequent in subacute disease.

Systemic embolization can lead to:

• Neurologic events – ischemic stroke, intracerebral hemorrhage, mycotic aneurysm; cryptogenic strokes in younger patients warrant evaluation for IE and hypercoagulable states.^[6]
• Renal infarcts or glomerulonephritis – flank pain, hematuria, renal dysfunction.
• Splenic infarcts – LUQ pain, splenic abscess.
• Peripheral arterial emboli – limb ischemia.

Right‑Sided Endocarditis

Often seen in IVDU or catheter‑associated infection:

• More commonly involves the tricuspid valve.
• Presents with fever, bacteremia, septic pulmonary emboli causing pleuritic chest pain, cough, hemoptysis, and multiple peripheral lung nodules or cavitary lesions on imaging.

Diagnosis

Diagnosis of endocarditis integrates clinical features, blood cultures, and imaging. The modified Duke criteria are widely used to classify IE as definite, possible, or rejected based on major and minor criteria.^[3]

Modified Duke Criteria (Conceptual Overview)

Major criteria include:

• Positive blood cultures with typical IE organisms from at least two separate cultures or persistently positive cultures.
• Evidence of endocardial involvement on echocardiography – vegetations, abscess, new dehiscence of prosthetic valve, or new valvular regurgitation.

Minor criteria include:

• Predisposing heart condition or IVDU.
• Fever ≥38°C.
• Vascular phenomena – emboli, Janeway lesions, intracranial hemorrhage, mycotic aneurysm.
• Immunologic phenomena – Osler nodes, Roth spots, glomerulonephritis, positive rheumatoid factor.
• Microbiologic evidence not meeting major criteria.

Initial Workup

• Blood cultures – obtain at least three sets from separate venipuncture sites before antibiotics if clinically feasible.
• Laboratory tests – CBC (often anemia, leukocytosis), ESR/CRP elevated, renal and hepatic function, urinalysis (microscopic hematuria, RBC casts), RF may be positive.
• Echocardiography
  • Transthoracic echo (TTE) – first‑line; good specificity but lower sensitivity for small vegetations and prosthetic valves.
  • Transesophageal echo (TEE) – higher sensitivity; recommended in prosthetic valves, suspected complications (abscess, paravalvular leak), or nondiagnostic TTE with high clinical suspicion.^[3]
• Advanced imaging
  • Nuclear imaging (e.g., SPECT/CT, PET/CT) can help detect prosthetic valve infection, paravalvular abscess, or extracardiac septic foci in complex or equivocal cases.^[3]

Management

Management of IE requires coordinated care involving cardiology, infectious diseases, and often cardiac surgery. Key components include early diagnosis, prompt targeted antimicrobial therapy, and timely surgical intervention when indicated.

Empiric Antimicrobial Therapy

Empiric therapy should cover typical organisms and be adjusted when culture results and susceptibilities return. Regimens depend on clinical context and local resistance patterns, but general principles are:

• Native valve, community-acquired, no IVDU
  • Empiric IV regimen often includes a beta‑lactam (e.g., ceftriaxone) plus vancomycin to cover viridans streptococci, S. aureus (including MRSA), and enterococci until cultures guide therapy.
• Healthcare-associated / prosthetic valve
  • Broad coverage with vancomycin plus an anti‑pseudomonal beta‑lactam (e.g., cefepime or piperacillin‑tazobactam), with or without gentamicin, is often used initially.
• IVDU right‑sided IE
  • Empiric therapy should strongly cover S. aureus, typically with vancomycin until susceptibility for MSSA vs MRSA is known.

Definitive therapy is organism‑specific and usually requires 4–6 weeks of IV antibiotics, timed from the first negative blood culture. Shorter courses may be appropriate in selected uncomplicated right‑sided IE in IVDU; exam questions typically emphasize longer durations for left‑sided or prosthetic valve disease.

Indications for Early Surgery

Cardiac surgery (valve repair or replacement, debridement, device removal) is indicated when there is high risk of death or irreversible damage with medical therapy alone. Common indications include:

• Heart failure due to acute severe valvular regurgitation or obstruction.
• Uncontrolled infection – persistent bacteremia or fever despite appropriate antibiotics, perivalvular abscess, fistula, or pseudoaneurysm.^[5]
• Prevention of embolism – large mobile vegetations (e.g., >10 mm) with prior embolic events, especially on the mitral valve.
• Prosthetic valve endocarditis with dehiscence, severe dysfunction, or abscess.

Transcatheter device closure of paravalvular leaks can improve regurgitation and HF but may itself be complicated by IE, device embolization, or residual leak, necessitating surgical correction in selected patients.^[5]

Adjunctive and Supportive Care

• Source control – remove infected catheters, infected devices, and nonessential intravascular lines as soon as feasible.^[1]
• Management of complications – treat heart failure with standard therapy; manage embolic stroke, splenic and renal complications in collaboration with neurology and surgery.
• Dental evaluation and treatment – especially before elective valve surgery and in high‑risk patients to eliminate chronic oral sources of bacteremia.^[4]

Endocarditis Prophylaxis

Antibiotic prophylaxis is no longer recommended for most patients, but guidelines support prophylaxis for select high‑risk groups undergoing procedures likely to cause bacteremia with organisms that commonly cause IE. Contemporary guideline assessments and decision aids increasingly use decision support tools, including large language models, to clarify indications.^[2]

High‑risk groups typically include:

• Prosthetic heart valves or prosthetic material used for valve repair.
• Prior history of infective endocarditis.
• Certain congenital heart diseases (unrepaired cyanotic lesions, or repaired with residual defects adjacent to prosthetic material).
• Cardiac transplant recipients with valvulopathy.

The highest‑yield indication for exams is prophylaxis before high‑risk dental procedures in these high‑risk cardiac patients, emphasizing the importance of oral health in systemic disease prevention.^[4]

Complications

Major complications of IE include:

• Heart failure – from severe valvular regurgitation or obstruction, the most common cause of death.
• Perivalvular extension – abscess, fistula, pseudoaneurysm, conduction defects (e.g., heart block).
• Embolic events – stroke, splenic and renal infarcts, limb ischemia, pulmonary emboli (in right‑sided IE).
• Mycotic aneurysms – intracranial or systemic arterial aneurysms due to septic emboli.
• Persistent sepsis and multiorgan failure.
• Device and prosthesis dysfunction – including paravalvular leaks, prosthetic dehiscence, and failure of transcatheter closure devices.^[5]

Key Clinical Pearls for Exams

• Always consider IE in patients with unexplained fever and a heart murmur or predisposing risk factor (prosthetic valve, IVDU, intracardiac device, hemodialysis catheter).
• Multiple positive blood cultures with typical organisms plus echocardiographic vegetations strongly support the diagnosis.
• Use the modified Duke criteria framework: major (positive cultures, echo findings) + minor (predisposition, fever, vascular and immunologic phenomena).^[3]
• Right‑sided IE (often tricuspid) is strongly associated with IVDU and presents with septic pulmonary emboli.
• Classic peripheral stigmata (Osler nodes, Janeway lesions, Roth spots) are low sensitivity but high yield on exams and help differentiate vascular vs immunologic phenomena.
• Persistent bacteremia or fever despite appropriate antibiotics should prompt evaluation for perivalvular abscess, device infection, or prosthetic valve complications and early surgical consultation.^[5]
• Prosthetic valve and device‑related IE are increasing in frequency; suspect in patients with new heart failure, hemolytic anemia, or signs of IE after valve or device intervention.^[5]
• Poor oral health is a major modifiable risk factor; dental evaluation and treatment are crucial components of prevention in high‑risk patients.^[4]
• Advanced imaging such as SPECT/CT or PET/CT can be useful in complex prosthetic valve IE when echocardiography is equivocal, particularly for detecting abscesses and metastatic infection.^[3]

Summary

Endocarditis is a life‑threatening infection of the endocardial surface of the heart that demands early recognition, prompt diagnostic workup with blood cultures and echocardiography, and prolonged targeted antimicrobial therapy. Understanding risk factors, microbiology, clinical presentations, and the indications for surgical intervention is essential for safe clinical practice and high performance on exams. Preventive strategies, particularly optimization of oral health and appropriate prophylaxis in high‑risk individuals, play a central role in reducing disease burden.^{[4], [3]}